menu search

Basilea pharmaceutica ag: basilea reports strong financial results 2022 based on successful implementation of new strategy

22% year-on-year increase of royalty income from antifungal cresemba ® Operating profit of CHF 18.5 mi...

February 14, 2023, 6:29 am

Basilea reports 2022 revenue of chf 148 million

Basilea Pharmaceutica said Wednesday revenue contributions from cresemba and Zevtera are expected to am...

January 11, 2023, 7:29 pm

Continued strong cresemba® (isavuconazole) sales by astellas in the u.s. trigger chf 20 million sales milestone payment to basilea

Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial a...

January 9, 2023, 6:29 am


Search within

Pages Search Results: